Search the Newsreel

What's Going On With Cascades Inc. Stock Tuesday?

HLE Glascoat shares hit 20% lower circuit as Q1 net profit falls 81% YoY

Will Burcon NutraScience Corporation (BU) Beat Earnings Estimates in Its Next Report?

Cascades (TSE:CAS) Reaches New 12-Month High on Analyst Upgrade

Banca Monte Dei Paschi Siena Aktie: 1,118 Milliarden Nettogewinn

Athabasca Oil (TSX:ATH) Following Q2 Results And High End Guidance, Is The Valuation Fair?

How Exclusive James Hardie Deal and Capital Returns Will Impact Boise Cascade (BCC) Investors

Boise Cascade (BCC) recently reported strong Q2 2026 results, including US$1.83 billion in sales and US$57.34 million in net income. The company secured an exclusive nationwide distribution agreement with James Hardie, making its Building Materials Distribution division the sole U.S. distributor for James Hardie's …

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275

Morgan Stanley has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its target price at $275. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.

HLE Glascoat Sees Profit Squeeze in Q1 FY27 but Banks on Strong Order Book and Demand Revival

Masco Corp (MAS) Shares Fall 3.6% -- GF Value Says Still Overval

Masco Corp (MAS) shares recently fell by 3.6% to $74.72, and according to GuruFocus's GF Value, the stock is still considered 2.1% overvalued compared to its intrinsic value of $73.18. Despite this, the company boasts a strong GF Score of 89/100, driven by high …

Cascades (TSE:CAS) Stock Price Expected to Rise, Desjardins Analyst Says

Royal Bank Of Canada Issues Positive Forecast for Cascades (TSE:CAS) Stock Price

HLE Glascoat Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Vascon Engineers to Host Q1 FY27 Earnings Call on August 14

Erasca appoints Charles Fuchs as R&D president

Erasca Inc. (NASDAQ:ERAS) has appointed Charles S. Fuchs, M.D., M.P.H., as its new president of research and development. Dr. Fuchs brings over 30 years of oncology experience, including leadership roles at Genentech and Roche, where he oversaw the development of several approved therapies. Erasca …

Charles Fuchs Brings More Than 3 Decades in Oncology to Erasca

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has appointed Charles S. Fuchs, M.D., M.P.H., as president of research and development. Dr. Fuchs brings over three decades of oncology leadership and expertise in drug development, scientific innovation, and patient care, with a focus on …

Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Seek Leadership in a Securities Fraud Lawsuit by August 10, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, which …

LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?

LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% …

5 Revealing Analyst Questions From Boise Cascade’s Q2 Earnings Call

Boise Cascade (BCC) reported strong Q2 results, exceeding analyst expectations for revenue and non-GAAP profit, driven by its integrated manufacturing and distribution model and higher commodity product prices. The company is navigating a significant transition with its James Hardie partnership, which analysts probed regarding …

Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT

Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing …

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

Hagens Berman is investigating a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims Erasca misled investors about its oncology candidate, ERAS-0015, regarding its competitive advantage, safety, and intellectual property, leading to a significant stock decline after …

Is Cascades (TSX:CAS) Fully Valued After Its Q2 Profit Turnaround And Price Increase?

Cascades Q2 Earnings Call Highlights

Key Points Interested in Cascades Inc.? Here are five stocks we like better. Cascades exceeded second-quarter expectations, with sequential improvements in both major segments. Packaging sales rose 8% to CAD 772 million and adjusted EBITDA increased 16% to CAD 120 million, while tissue sales …

Boise Cascade Co (BCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Boise Cascade Co (BCC), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company ranks 36 out of 54 in the Homebuilding & Construction Supplies industry with an average price target …

Ascentage Pharma Group International (SEHK:6855) Adds Global Dealmakers As Fair Value Debate Builds

Cascades Inc. Signals Momentum In Latest Earnings Call

(ASND) Volatility Zones as Tactical Triggers

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND), highlighting a mid-channel oscillation pattern and a strong 27.6:1 risk-reward setup. It provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report identifies positive …

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August …

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Erasca, Inc. (NASDAQ: ERAS). Investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses, are encouraged to contact KSF, with an application deadline for …

Ardmore Shipping Corp (ASC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ardmore Shipping Corp (ASC), detailing its current earnings forecast score, average price target, and analyst ratings. It also includes peer comparisons and answers frequently asked questions about expected revenue, price targets, and past and future EPS performance. …

LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

LeMaitre Vascular, Inc. recently missed its statutory earnings estimates, causing its shares to drop by 21%. Despite the earnings miss, revenue remained in line with predictions, and analysts have largely maintained their price targets, though they slightly downgraded next year's EPS forecasts. The company …

Boise Cascade (NYSE:BCC) Upgraded to "Buy" at Wall Street Zen

Boise Cascade (NYSE:BCC) received an upgrade from "Hold" to "Buy" by Wall Street Zen, despite the broader analyst consensus remaining at "Hold" with an average price target of $93.60. The company's shares increased by 2.9%, trading near its 12-month high and above moving averages, …

Ascentage Pharma Group International (AAPG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ascentage Pharma Group International (AAPG), highlighting that 9 analysts currently recommend a "Buy" rating with a target price indicating a significant upside. The report includes current stock performance and a peer comparison, but notes that specific financial …

Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) and its officers, alleging violations of federal securities laws. The lawsuit claims that Erasca made misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons and …

Cascades (TSX:CAS) Stock Rally Faces Slower Earnings Momentum

Ardmore Shipping (ASC) Q2 2026 Earnings Call Transcript